International Journal of Radiation Oncology * Biology * Physics
Volume 69, Issue 4 , Pages 1246-1253 , 15 November 2007

Differential Radiosensitizing Potential of Temozolomide in MGMT Promoter Methylated Glioblastoma Multiforme Cell Lines

  • Krista A. van Nifterik, M.Sc.

      Affiliations

    • Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands
    • Department of Neurogenetics, Academic Medical Center, Amsterdam, The Netherlands
    • ,
  • Jaap van den Berg, B.S.

      Affiliations

    • Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Lukas J.A. Stalpers, M.D., Ph.D.

      Affiliations

    • Department of Radiotherapy, Academic Medical Center, Amsterdam, The Netherlands
    • ,
  • M. Vincent M. Lafleur, Ph.D.

      Affiliations

    • Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Sieger Leenstra, M.D., Ph.D.

      Affiliations

    • Department of Neurosurgery, Academic Medical Center, Amsterdam, The Netherlands
    • ,
  • Ben J. Slotman, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Theo J.M. Hulsebos, Ph.D.

      Affiliations

    • Department of Neurogenetics, Academic Medical Center, Amsterdam, The Netherlands
    • ,
  • Peter Sminia, Ph.D.

      Affiliations

    • Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands
    • Corresponding Author InformationReprint requests to: Peter Sminia, Ph.D., Division of Radiobiology, Department of Radiation Oncology, VU University Medical Center, Bldg: Faculty of Medicine, Room J-392, Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands. Tel: (+31) 20-4448355; Fax: (+31) 20-4448285

Received 25 April 2007 ,Revised 28 June 2007 ,Accepted 30 July 2007.

References 

  1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996
  2. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 2004;10:1871–1874
  3. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003
  4. Brennand J, Margison GP. Reduction of the toxicity and mutagenicity of alkylating agents in mammalian cells harboring the Escherichia coli alkyltransferase gene. Proc Natl Acad Sci U S A. 1986;83:6292–6296
  5. Tisdale MJ. Antitumor imidazotetrazines—XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem Pharmacol. 1987;36:457–462
  6. Wedge SR, Porteus JK, May BL, et al. Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: A comparative study in vitro. Br J Cancer. 1996;73:482–490
  7. Karran P, Macpherson P, Ceccotti S, et al. O6-methylguanine residues elicit DNA repair synthesis by human cell extracts. J Biol Chem. 1993;268:15878–15886
  8. Ochs K, Kaina B. Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res. 2000;60:5815–5824
  9. Gerson SL. MGMT: Its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004;4:296–307
  10. Hotta T, Saito Y, Fujita H, et al. O6-alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications. J Neurooncol. 1994;21:135–140
  11. Belanich M, Pastor M, Randall T, et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res. 1996;56:783–788
  12. Silber JR, Blank A, Bobola MS, et al. O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: Frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res. 1999;5:807–814
  13. Qian XC, Brent TP. Methylation hot spots in the 5' flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. Cancer Res. 1997;57:3672–3677
  14. Watts GS, Pieper RO, Costello JF, et al. Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol. 1997;17:5612–5619
  15. Esteller M, Hamilton SR, Burger PC, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999;59:793–797
  16. Paz MF, Yaya-Tur R, Rojas-Marcos I, et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res. 2004;10:4933–4938
  17. Donson AM, Addo-Yobo SO, Handler MH, et al. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer. 2007;48:403–407
  18. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350–1354
  19. Chakravarti A, Erkkinen MG, Nestler U, et al. Temozolomide-mediated radiation enhancement in glioblastoma: A report on underlying mechanisms. Clin Cancer Res. 2006;12:4738–4746
  20. Hermisson M, Klumpp A, Wick W, et al. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem. 2006;96:766–776
  21. van Rijn J, Heimans JJ, van den Berg J, et al. Survival of human glioma cells treated with various combinations of temozolomide and X-rays. Int J Radiat Oncol Biol Phys. 2000;47:779–784
  22. Wedge SR, Porteous JK, Glaser MG, et al. In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs. 1997;8:92–97
  23. Gerlach B, Harder AH, Hulsebos TJ, et al. Radiosensitivity and TP 53, EGFR amplification and LOH10 analysis of primary glioma cell cultures. Strahlenther Onkol. 2002;178:491–496
  24. Kleihues P, Burger PC, Collins VP, et al. Glioblastoma. In:  Kleihues P,  Cavanee WK editor. Pathology and genetics, tumours of the nervous system. World Health Organization classification of tumours. Lyon: IARC Press; 2000;p. 29–39
  25. von Deimling A, Fimmers R, Schmidt MC, et al. Comprehensive allelotype and genetic analysis of 466 human nervous system tumors. J Neuropathol Exp Neurol. 2000;59:544–558
  26. van Nifterik KA, Elkhuizen PH, van Andel RJ, et al. Genetic profiling of a distant second glioblastoma multiforme after radiotherapy: Recurrence or second primary tumor?. J Neurosurg. 2006;105:739–744
  27. Nygren AO, Ameziane N, Duarte HM, et al. Methylation-specific MLPA (MS-MLPA): Simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res. 2005;33:e128
  28. Balmforth AJ, Ball SG, Freshney RI, et al. D-1 dopaminergic and beta-adrenergic stimulation of adenylate cyclase in a clone derived from the human astrocytoma cell line G-CCM. J Neurochem. 1986;47:715–719
  29. Franken NAP, Rodermond HM, Stap J, et al. Clonogenic assay of cells in vitro. Nature Protocols. 2006;1:2315–2319
  30. van Rijn J, van den Berg J, Meijer OW. Proliferation and clonal survival of human lung cancer cells treated with fractionated irradiation in combination with paclitaxel. Int J Radiat Oncol Biol Phys. 1995;33:635–639
  31. Bigner SH, Humphrey PA, Wong AJ, et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res. 1990;50:8017–8022
  32. Pandita A, Aldape KD, Zadeh G, et al. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer. 2004;39:29–36
  33. Leenstra S, Oskam NT, Bijleveld EH, et al. Genetic sub-types of human malignant astrocytoma correlate with survival. Int J Cancer. 1998;79:159–165
  34. Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001;93:1246–1256
  35. Tada K, Shiraishi S, Kamiryo T, et al. Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: Correlation with patient age and survival. J Neurosurg. 2001;95:651–659
  36. Terada K, Tamiya T, Daido S, et al. Prognostic value of loss of heterozygosity around three candidate tumor suppressor genes on chromosome 10q in astrocytomas. J Neurooncol. 2002;58:107–114
  37. Wemmert S, Ketter R, Rahnenfuhrer J, et al. Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. Neoplasia. 2005;7:883–893
  38. Roos WP, Batista LF, Naumann SC, et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene. 2007;26:186–197
  39. Srivenugopal KS, Shou J, Mullapudi SR, et al. Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents. Clin Cancer Res. 2001;7:1398–1409
  40. Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer. 2003;3:117–129
  41. Haas-Kogan DA, Kogan SS, Yount G, et al. p53 function influences the effect of fractionated radiotherapy on glioblastoma tumors. Int J Radiat Oncol Biol Phys. 1999;43:399–403

 Supported by Dutch Cancer Society Grant No. VU 2000-2149.

 Conflict of interest: none.

PII: S0360-3016(07)03859-X

doi: 10.1016/j.ijrobp.2007.07.2366

International Journal of Radiation Oncology * Biology * Physics
Volume 69, Issue 4 , Pages 1246-1253 , 15 November 2007

Article Tools

* Image Usage & Resolution